Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05206513 · ClinicalTrials.gov registry record · Phase 3

Study to Assess the Efficacy, Safety, and Tolerability of Valbenazine for the Treatment of Dyskinesia Due to Cerebral Palsy

A Phase 3 study of Cerebral Palsy and Dyskinesia, sponsored by Neurocrine Biosciences.

Active
Registry status
Phase 3
Development phase
86
Enrollment target
20
Study locations

NCT05206513 is a Phase 3 study of Cerebral Palsy and Dyskinesia that is active but no longer recruiting, run by Neurocrine Biosciences. The registered enrollment target is 86 participants, below the 228-participant average among 91 other Cerebral Palsy trials with a reported enrollment target (62% lower). The trial reports 20 study locations across 15 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05206513, a Phase 3 study of Cerebral Palsy and Dyskinesia, is active but no longer recruiting, sponsored by Neurocrine Biosciences.

ACTIVE NOT RECRUITING
Registry status
Phase 3
Development phase
86 participants
Enrollment target
20
Study locations

Study Summary

The primary objective of this study is to evaluate the efficacy of valbenazine versus placebo on improving chorea in pediatric and adult participants who have dyskinesia due to cerebral palsy (DCP) with choreiform movements.

Conditions Studied

Cerebral Palsy Dyskinesia

Interventions

  • DRUG Placebo
  • DRUG Valbenazine

Study Locations (20)

Florida

  • Neurocrine Clinical Site - Gulf Breeze
  • Neurocrine Clinical Site - Miami
  • Neurocrine Clinical Site - Orlando

Texas

  • Neurocrine Clinical Site - Dallas
  • Neurocrine Clinical Site - Fort Worth
  • Neurocrine Clinical Site - Houston

Ohio

  • Neurocrine Clinical Site - Cincinnati
  • Neurocrine Clinical Site - Columbus

California

  • Neurocrine Clinical Site - San Diego

Colorado

  • Neurocrine Clinical Site - Aurora

Connecticut

  • Neurocrine Clinical Site - Stamford

Illinois

  • Neurocrine Clinical Site - Chicago

Maryland

  • Neurocrine Clinical Site - Baltimore

Trial Details

FieldValue
Enrollment Target 86 participants
Start Date 2022-04-15
Est. Completion 2026-06
Phase Phase 3

Sponsor

Neurocrine Biosciences

65 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05206513

The ClinicalTrials.gov registry entry for NCT05206513 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 86 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 228-participant average among 91 other Cerebral Palsy trials with a reported enrollment target (62% lower). The listed sponsor is Neurocrine Biosciences, which has 65 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Cerebral Palsy appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT05206513 reports 20 study locations spanning 15 distinct geographic areas - top geographies include Florida, Texas, Ohio.

Frequently Asked Questions

What is clinical trial NCT05206513 about?

NCT05206513 is a clinical study titled "Study to Assess the Efficacy, Safety, and Tolerability of Valbenazine for the Treatment of Dyskinesia Due to Cerebral Palsy". The primary objective of this study is to evaluate the efficacy of valbenazine versus placebo on improving chorea in pediatric and adult participants who have dyskinesia due to cerebral palsy (DCP) with choreiform movements.

What is the current status of trial NCT05206513?

This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 86 participants. The study started on 2022-04-15. Estimated completion is 2026-06.

What conditions does trial NCT05206513 study?

This clinical trial studies the following conditions: Cerebral Palsy, Dyskinesia.

What interventions are being tested in trial NCT05206513?

The interventions under investigation include: Placebo (DRUG), Valbenazine (DRUG).

Who is sponsoring clinical trial NCT05206513?

This trial is sponsored by Neurocrine Biosciences, which has 65 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05206513 being conducted?

This trial has 20 study locations across California, Colorado, Connecticut, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Cerebral Palsy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Cerebral Palsy

All registered trials for this condition

Dyskinesia

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.